-
Dynavax Shares On The Mend As The Hepsilav Saga Continues
Monday, October 3, 2016 - 11:42am | 309Read More...Shares of Dynavax Technologies Corporation (NASDAQ: DVAX) surged by 20 percent Monday after the clinical-stage bio pharmaceutical company released a regulatory filing. In its filing, Dynavax said it received from the U.S. Food and Drug Administration a request for information concerning its...
-
Why Shares Of Valeant Pharmaceuticals Spiked
Monday, January 25, 2016 - 2:17pm | 205Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading higher by more than 6 percent on Monday after the company announced the Food and Drug Administration has accepted for review the Biologics License Application (BLA) the company submitted as part of a partnership with AstraZeneca...
-
Regeneron, Sanofi Announce FDA Has Accepted For Review BLA For Sarilumab
Friday, January 8, 2016 - 11:36am | 180Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) jointly announced Friday morning that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for sarilumab. Regeneron noted that the BLA for sarilumab contains data from...
-
Vericel Moving Up Following Submission Of Biologics Licence Application To The FDA
Tuesday, January 5, 2016 - 11:02am | 173Read More...Shares of Vericel Corp (NASDAQ: VCEL), a developer of cellular therapies for use in the treatment of patients with diseases and conditions, were trading higher by nearly 4 percent on Tuesday morning. The move higher in Vericel's stock follows the company's announcement on Monday that it has...
-
J.P. Morgan Maintains Neutral Rating On SGEN
Monday, May 2, 2011 - 9:57am | 192Read More...This morning, Seattle Genetics Inc. (NASDAQ: SGEN) announced that the FDA has accepted two Biologics License Application (BLA) filings for SGN-35/B, J.P. Morgan reports. “Vedotin (BV) as a treatment for relapse/refractory Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL),” J.P. Morgan...
